Updated CAPItello-281 data at #ESMO26

Deborah Mukherji· @dmukherji · X·2026-10-23 20:48· 2 days agoScore70

Body · original

In PTEN-deficient mHSPC, capivasertib + abiraterone improved median OS (57.4 vs 46.5 months; HR 0.82) and rPFS (35.5 vs 26.0 months).

Encouraging OS trend, but not statistically significant at this analysis #KarimFizazi @OncoAlert

288 views · 5 likes · 5 reposts · 0 replies

Conference abstracts

LBA56NCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Capivasertib (capi) + abiraterone (abi) vs placebo (pbo) + abi in patients (pts) with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC): Updated overall survival (OS) from CAPItello-281

https://esmocongress.esmo.org

Source: Deborah Mukherji · x.com